ReviewRSC advances2026
Liposomal nanoparticles as a drug delivery system for improved treatment of multiple myeloma.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Vaccine Adjuvants and Delivery Systems: A Comprehensive Review.International journal of molecular sciences · 2026Review
- Nanomedicine-Based Strategies for Multiple Myeloma Therapy.International journal of nanomedicine · 2026Review
- Editorial: Advancements in nanomedicine for targeted cancer therapy and imaging.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) remains a challenging type of hematological cancer, characterized by the growth and accumulation of clonal plasma cells within the bone marrow. Current traditional therapies, mainly conventional chemotherapeutics, demonstrate limited therapeutic capacity due to considerable side effects and drug resistance. In this direction, liposomal nanotherapeutics have emerged as a promising new strategy in cancer therapy, holding great potential to address the chemical and biological constraints of existing anticancer treatments. This review presents a summary of the latest developments in the application of targeted liposomal nanoparticles as a drug carrier system for the management of MM. Furthermore, it explores the challenges linked to creating efficient drug delivery systems, targeting methods, and the processes involved in controlled drug release.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.